Neurology AdvisorPlasma P-Tau217 Accurately Detects Preclinical Alzheimer Disease Pathology

Blood test for Alzheimer’s detects preclinical brain pathology with 87% accuracy in cognitively normal adults, matching expensive PET scans at fraction of cost. Meta-analysis of 7,834 participants validates plasma p-tau217 as scalable screening tool for identifying disease years before symptoms emerge.

⚖️ PROFESSIONAL IMPACT

• Plasma p-tau217 achieves 0.87 AUC for detecting amyloid-positive status without cognitive impairment, making blood-based preclinical screening clinically viable
• Simoa platform assays reached 0.91 AUC, outperforming other platforms and approaching PET imaging accuracy for identifying at-risk patients
• Test performs consistently across different amyloid PET cutoff methods, enabling standardized preclinical detection regardless of institutional imaging protocols
• High between-study heterogeneity (I²=90%) and predominance of educated White participants limit generalizability to diverse clinical populations

🎯 ACTION ITEMS

• Counsel patients that blood test detects Alzheimer’s pathology before memory loss begins
• Educate families that positive result indicates brain changes, not imminent dementia diagnosis
• Explain test identifies candidates for preventive trials and early intervention strategies
• Document that assay platform matters: Simoa-based tests show superior diagnostic accuracy

More in Biomarkers